BAJAJ BROKING

Notification
No new Notification messages
Suraksha Diagnostic IPO is Open!
Apply for the Suraksha Diagnostic IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Q2 FY'24-25 Results of Top Companies
Reliance, TCS, HDFC Bank & more: Explore key financial highlights from India's top quarterly results.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

CA Dawn to Sell 2.9% Stake in Indegene at ₹615 Per Share

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

Carlyle-backed CA Dawn plans to sell a 2.9% stake in Indegene via block deals at a floor price of ₹615 per share. The deal may generate ₹470 crore. Indegene reported a revenue of ₹1,969 crore and profit of ₹241 crore in December 2023.

CA Dawn news today

CA Dawn Investments, a Carlyle-backed private equity firm, is preparing to sell a 2.9% stake in Indegene Ltd through block deals. The floor price for the stake sale has been set at ₹615 per share. The transaction is expected to raise around ₹470 crore, based on the floor price, marking a significant move in the healthcare tech sector.

Also read: Solar Industries Secures ₹2,039 Crore Export Order for Defence Products

INDEGENE LIMITED

Trade

626.85-40.60 (-6.08 %)

Updated - 03 December 2024
634.00day high
DAY HIGH
616.00day low
DAY LOW
23339902
VOLUME (BSE)

Key Takeaways

  • Seller: CA Dawn Investments

  • Stake Sold: 2.9%

  • Floor Price: ₹615 per share

  • Expected Proceeds: ₹470 crore

  • Major Shareholders:

    • Nadathur Fareast Pte Ltd: 23.64%

    • CA Dawn Investments: 20.42%

    • Brighton Park Capital: 12%

Also read: Torrent Power to Raise ₹5,000 Crore via QIP at ₹1,503 Per Share 

Financial overview of Indegene

Indegene Ltd is a leading healthcare technology firm offering solutions to biopharmaceutical, biotech, and medical devices companies. The company recorded revenue from operations of ₹1,969 crore and a profit after tax of ₹241 crore for the period ending December 2023. The firm’s solutions play a pivotal role in the lifecycle of healthcare products, from development to market launch and sales optimisation.

Indegene Share Price Performance

Shares of Indegene closed at ₹665 on the BSE on December 2, down by ₹16.70 or 2.45%. Despite this dip, the stock remains a focal point in the market due to its potential for long-term growth.

Shareholder structure of Indegene

Shareholder

Stake (%)

Nadathur Fareast Pte Ltd

23.64%

CA Dawn Investments

20.42%

Brighton Park Capital

12%

The sale of a 2.9% stake in Indegene by CA Dawn is expected to bring significant market activity. The focus on a ₹615 floor price and the potential ₹470 crore proceeds underline the value of Indegene’s market position. The Indegene share price remains a key indicator for market watchers.

Also read: Protean eGov Technologies Secures ₹161 Crore CERSAI Project for CKYCRR 2

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs + Users

icon-with-text

4.8+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5000+ Cr MTF Book

icon-with-text